Fulgent Genetics, Inc. - 8-K Filing
Fulgent Genetics reports Q3 2026 revenue of $90.4 million and improves full-year Non-GAAP loss guidance. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $FLGT
Read the full article at SEC EDGAR
Part of the story MYRIAD GENETICS INC - 8-K Filing (4 articles)